Literature DB >> 23624057

HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques.

Jinyao Li1, Antonio Valentin, Viraj Kulkarni, Margherita Rosati, Rachel Kelly Beach, Candido Alicea, Drew Hannaman, Steven G Reed, Barbara K Felber, George N Pavlakis.   

Abstract

Vaccination with HIV/SIV DNAs elicits potent T-cell responses. To improve humoral immune responses, we combined DNA and protein in a co-immunization protocol using in vivo electroporation in mice and macaques. DNA&protein co-immunization induced higher antibody responses than DNA or protein alone, or DNA prime/protein boost in mice. DNA&protein co-immunization induced similar levels of cellular responses as those obtained by DNA only vaccination. The inclusion of SIV or HIV Env gp120 protein did not impair the development of cellular immune responses elicited by DNA present in the vaccine regimen. In macaques, the DNA&protein co-immunization regimen also elicited higher levels of humoral responses with broader cross-neutralizing activity. Despite the improved immunogenicity of DNA&protein co-immunization, the protein formulation with the EM-005 (GLA-SE) adjuvant further increased the anti-Env humoral responses. Dissecting the contribution of EM-005, we found that its administration upregulated the expression of co-stimulatory molecules and stimulated cytokine production, especially IL-6, by dendritic cells in vivo. These terminally differentiated, mature, dendritic cells possibly promote higher levels of humoral responses, supporting the inclusion of the EM-005 adjuvant with the vaccine. Thus, DNA&protein co-immunization is a promising strategy to improve the rapidity of development, magnitude and potency of the humoral immune responses.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Adjuvant; Antibody; Cellular responses; Dendritic cell maturation; Electroporation; Humoral responses; Immunization; Neutralizing antibody; Vaccination

Mesh:

Substances:

Year:  2013        PMID: 23624057      PMCID: PMC7561005          DOI: 10.1016/j.vaccine.2013.04.037

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  50 in total

1.  Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.

Authors:  Vainav Patel; Antonio Valentin; Viraj Kulkarni; Margherita Rosati; Cristina Bergamaschi; Rashmi Jalah; Candido Alicea; Jacob T Minang; Matthew T Trivett; Claes Ohlen; Jun Zhao; Marjorie Robert-Guroff; Amir S Khan; Ruxandra Draghia-Akli; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

Review 2.  Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo.

Authors:  Natalie A Hutnick; Devin J F Myles; Chaoran Billie Bian; Karuppiah Muthumani; David B Weiner
Journal:  Curr Opin Virol       Date:  2011-09-07       Impact factor: 7.090

3.  Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a murine model.

Authors:  Jun-Ichi Imoto; Eiji Konishi
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

4.  High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation.

Authors:  Jiangmei Yin; Anlan Dai; Jonathan Lecureux; Tatiana Arango; Michele A Kutzler; Jian Yan; Mark G Lewis; Amir Khan; Niranjan Y Sardesai; David Montefiore; Ruth Ruprecht; David B Weiner; Jean D Boyer
Journal:  Vaccine       Date:  2010-12-31       Impact factor: 3.641

5.  Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate.

Authors:  Ranajit Pal; Shixia Wang; V S Kalyanaraman; B C Nair; Stephen Whitney; Timothy Keen; Lindsey Hocker; Lauren Hudacik; Nicolas Rose; Anthony Cristillo; Innocent Mboudjeka; Siyuan Shen; Te-Hui Wu-Chou; David Montefiori; John Mascola; Shan Lu; Phillip Markham
Journal:  J Med Primatol       Date:  2005-10       Impact factor: 0.667

6.  Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens.

Authors:  Miwa Kuwahara; Eiji Konishi
Journal:  Clin Vaccine Immunol       Date:  2010-07-28

7.  Intradermal immunization improves protective efficacy of a novel TB vaccine candidate.

Authors:  Susan L Baldwin; Sylvie Bertholet; Maria Kahn; Irina Zharkikh; Gregory C Ireton; Thomas S Vedvick; Steven G Reed; Rhea N Coler
Journal:  Vaccine       Date:  2009-03-26       Impact factor: 3.641

8.  Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations.

Authors:  Ryan C Anderson; Christopher B Fox; Timothy S Dutill; Narek Shaverdian; Tara L Evers; Garrett R Poshusta; James Chesko; Rhea N Coler; Martin Friede; Steven G Reed; Thomas S Vedvick
Journal:  Colloids Surf B Biointerfaces       Date:  2009-08-20       Impact factor: 5.268

9.  Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Authors:  Rhea N Coler; Sylvie Bertholet; Magdalini Moutaftsi; Jeff A Guderian; Hillarie Plessner Windish; Susan L Baldwin; Elsa M Laughlin; Malcolm S Duthie; Christopher B Fox; Darrick Carter; Martin Friede; Thomas S Vedvick; Steven G Reed
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

10.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Authors:  Morgane Rolland; Paul T Edlefsen; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Tomer Hertz; Allan C deCamp; Chris Carrico; Sergey Menis; Craig A Magaret; Hasan Ahmed; Michal Juraska; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; Jason S McLellan; Ivelin Georgiev; Peter D Kwong; Jonathan M Carlson; Nelson L Michael; William R Schief; Peter B Gilbert; James I Mullins; Jerome H Kim
Journal:  Nature       Date:  2012-09-10       Impact factor: 49.962

View more
  45 in total

1.  An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.

Authors:  Zhanna Shubin; Weizhong Li; Bhawna Poonia; Guido Ferrari; Celia LaBranche; David Montefiori; Xiaoping Zhu; C David Pauza
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

Review 2.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

3.  Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Authors:  Susan Zolla-Pazner; Rebecca Powell; Sara Yahyaei; Constance Williams; Xunqing Jiang; Wei Li; Shan Lu; Shixia Wang; Chitra Upadhyay; Catarina E Hioe; Max Totrov; Xiangpeng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

Review 4.  Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.

Authors:  Ivelin S Georgiev; M Gordon Joyce; Tongqing Zhou; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

Review 5.  Chemokine-mediated immune responses in the female genital tract mucosa.

Authors:  Maud Deruaz; Andrew D Luster
Journal:  Immunol Cell Biol       Date:  2015-03-17       Impact factor: 5.126

6.  DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.

Authors:  Veena Menon; Victor I Ayala; Sneha P Rangaswamy; Irene Kalisz; Stephen Whitney; Lindsey Galmin; Asma Ashraf; Celia LaBranche; David Montefiori; Nikolai Petrovsky; Vaniambadi S Kalyanaraman; Ranajit Pal
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

7.  Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes.

Authors:  Jamie F S Mann; Paul F McKay; Anezka Fiserova; Katja Klein; Alethea Cope; Paul Rogers; Julie Swales; Michael S Seaman; Behazine Combadiere; Robin J Shattock
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

8.  Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Authors:  Timothy R Fouts; Kenneth Bagley; Ilia J Prado; Kathryn L Bobb; Jennifer A Schwartz; Rong Xu; Robert J Zagursky; Michael A Egan; John H Eldridge; Celia C LaBranche; David C Montefiori; Hélène Le Buanec; Daniel Zagury; Ranajit Pal; George N Pavlakis; Barbara K Felber; Genoveffa Franchini; Shari Gordon; Monica Vaccari; George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-13       Impact factor: 11.205

9.  IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.

Authors:  Anthony L Desbien; Natasha Dubois Cauwelaert; Steven J Reed; Hilton R Bailor; Hong Liang; Darrick Carter; Malcolm S Duthie; Christopher B Fox; Steven G Reed; Mark T Orr
Journal:  J Immunol       Date:  2016-10-28       Impact factor: 5.422

10.  Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Authors:  Franco Pissani; Delphine C Malherbe; Jason T Schuman; Harlan Robins; Byung S Park; Shelly J Krebs; Susan W Barnett; Nancy L Haigwood
Journal:  Vaccine       Date:  2013-11-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.